

FOIA MARKER

**This is not a textual record. This is used as an
administrative marker by the William J. Clinton
Presidential Library Staff.**

Collection/Record Group: Clinton Presidential Records

Subgroup/Office of Origin: National AIDS Policy Office

Series/Staff Member:

Subseries:

OA/ID Number: 21065

FolderID:

Folder Title:

Pharmaceutical Executives Meeting, DC, 03/29/00

Stack:

S

Row:

67

Section:

1

Shelf:

3

Position:

1

Withdrawal/Redaction Sheet

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. note	handwritten, names and personal information (partial) (1 page)	nd	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office

OA/Box Number: 21065

FOLDER TITLE:

Pharmaceutical Executives Meeting, DC, 03/29/00

2007-1550-F

kc1274

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

**FAX TRANSMITTAL**

If you receive this transmission by mistake or do not receive all of the pages,
please call Carol Coad at (202) 835-3490.

DATE: March 29, 2000**Pages (w/cover):** 1

TO: Sandy Thurman
Attn: Cheryl
FAX #: 456-2439

FROM: Carol Coad
International Affairs
Phone: 202-835-3490
Fax: 202-835-3438

COMMENTS:

Cheryl,

In accordance with Shannon Herzfeld's and Ms. Thurman's conversation at their meeting this morning, please schedule a follow-up meeting with Ms. Thurman and Ms. Herzfeld. Ms. Herzfeld proposes meeting again on April 11. She is also available the afternoon of April 10. Please call me to confirm the date and time of the meeting.

Thank you,

Carol Coad
202/835-3490

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. note	handwritten, names and personal information (partial) (1 page)	nd	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office

OA/Box Number: 21065

FOLDER TITLE:

Pharmaceutical Executives Meeting, DC, 03/29/00

2007-1550-F

kc1274

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]


C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]





FAX TRANSMITTAL

If you receive this transmission by mistake or do not receive all of the pages,
please call Carol Coad at (202) 835-3490.

DATE: March 28, 2000

Pages (w/cover): 1

TO: Sheryl
456-2439

FROM: Carol Coad
Phone: 202-835-3490
Fax: 202-835-3438

COMMENTS:

Sheryl,

Following are the names of the pharmaceutical executives who will accompany Shannon Herzfeld to the meeting with Ms. Thurman tomorrow at 11:00 a.m.

Thomas Bornbelles, Merck & Co.
Mark Speaker, Bristol Myers Squibb & Co.
William Schuyler, Glaxo-Wellcome
Aracelia Vila, Schering-Plough
Julie Rabinowitz, American Home Products

Please call me if you need additional information.

Pharmaceutical Research and Manufacturers of America

1100 Fifteenth Street, N.W., Suite 900, Washington, D.C. 20005

delivered

Office of the Coordinator for Business Affairs

U.S. Department of State

2201 C Street, Room 2318

Washington, D.C. 20520

Date: 3/24/00 Pages including cover: 3

To: Cheryl Bauerle

Organization: National Aids Policy Office

Phone: () 456-2437 Fax: () 456-2439

From: M. Karen Walker
Phone: (202) 647-0079
Fax: (202) 647-3953
E-mail: walkermk@state.gov

Message:

Cheryl - as promised!
Karen

Hi, Cheryl.

Thanks for taking my call today.

As promised, here are the details of the pharmaceuticals roundtable:

Date: Wednesday, March 29

Time: 2 - 3:30

Place: State Department
Room 1408
(one of the building's first-floor conference rooms)

RSVP: To M. Karen Walker
Office of Business Affairs
(202) 647-0079.

If you are coming in from outside and don't have a DOS badge, I'll need DOB and SSN when you RSVP.

Companies Merck
Confirmed: Schering Plough
Bristol Myers-Squibb
PhRMA

Invitations have been extended to Eli Lilly and Pfizer.

Private sector participation is being organized by the Business Council for International Understanding, one of my office's partnering organizations. (If you'd like some background on BCIU I have that handy.)

About the Roundtable:

This roundtable was requested by the pharmaceutical company reps, who wanted an opportunity to brief State Department officials on their activities related to HIV/AIDS. The roundtable will offer the companies an opportunity to address current and planned activities in prevention, treatment and R&D; obstacles to delivery of health care services in developing countries; and potential opportunities for a greater private sector role in addressing global health issues.

Initially Nancy had planned doing remarks, as the companies had expressed an interest in hearing the USG perspective and latest developments on policy initiatives. Given the sensitivities associated with the work of the Interagency Subcommittee on Economics, Trade and Finance, we may shift to a two-pronged agenda of company briefs followed by Q and A.

Materials Etc.

We're not planning on handing out anything other than the excerpt from the HIV/AIDS US International Response Report, on the role of the pharmaceutical industry. Through BCIU, the companies have been invited to provide fact sheets or other similar materials on their company-directed programs, which I can package as a hand-out for participants (and for those interested but unable to come.)

Really appreciate your help getting this into the queue in the Director's Office. Please let me know who from the National Aids Policy Office would like to attend.

Thanks again!